113 results on '"Benedict, Ralph"'
Search Results
2. Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis (S42.008)
3. Brain MRI atrophy quantification in MS
4. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses
5. Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis
6. Cognition in multiple sclerosis: State of the field and priorities for the future
7. Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis: Post Hoc Analysis from the EXPAND Study (P5-4.006)
8. Innovative Comparative Study Assessing the Effect of Siponimod on Reactive Microglia/Astrocytes in Patients With Secondary Progressive Multiple Sclerosis: Study Design (P6-4.007)
9. A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
10. DeepGRAI (Deep Gray Rating via Artificial Intelligence) Provides Feasible and Clinically Meaningful Thalamic Volume Measurement on Multi-Center Clinical-Quality T2-FLAIR Images (P12-4.009)
11. Thalamic Volume Predicts Recovery from Cognitive Relapse (P14-4.010)
12. A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)
13. Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
14. Visual Assessment and its Relationship with Cognitive Performance in Multiple Sclerosis: Optical Coherence Tomography and Low-Contrast Letter Acuity Study (2725)
15. Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study (2275)
16. Importance of detecting clinical and cognitive variables to mitigate unemployment in patients with Multiple Sclerosis in Argentina (4173)
17. A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis (4458)
18. Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130)
19. Correlations Between Four Common Measures of Cognition in Patients With Secondary Progressive Multiple Sclerosis (4000)
20. Long-standing Multiple Sclerosis Neurodegeneration: Volumetric MRI Comparison to Parkinson’s Disease, Mild Cognitive Impairment, Alzheimer’s Disease and Elderly Healthy Controls (2393)
21. Predicting Longitudinal Cognitive Decline in MS Using Baseline Clinical Routine T2-FLAIR MRI (2577)
22. Alteration of Resting-state Functional Connectivity in Response to Structural Disruption Differs Between Well-Established Functional Networks in Multiple Sclerosis (1931)
23. Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis (1905)
24. Cortical and Deep Gray Matter Perfusion is Associated with Physical and Cognitive Performance in Multiple Sclerosis Patients (2340)
25. Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290)
26. Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128)
27. Effect of Siponimod on Disability in EXPAND Re-examined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS (4051)
28. Diffusion Tensor Imaging of the Nucleus Basalis of Meynert Reveals Associations with Cognitive State in Patients with Multiple Sclerosis (4628)
29. Artificial Intelligence-based Thalamic Volumetry Is Fast, Reliable, and Generalizable to Large, Heterogeneous Datasets Using Only Clinical Quality T2-FLAIR MRI (4846)
30. Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis (P3.2-051)
31. Deep learning enables thalamic atrophy measurement on clinical quality T2 FLAIR images (P5.2-057)
32. A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
33. The association between serum neurofilament light chain and OCT measures in multiple sclerosis (S37.007)
34. LIFEware Life Satisfaction and Pessimism are Correlated with the Beck Depression Inventory-Fast Screen and with Disability Progression in Individuals with Multiple Sclerosis (P3.2-009)
35. Thalamic nuclei volumes as markers of clinical disability and cognitive dysfunction in multiple sclerosis (P5.2-069)
36. Concordance Between Structural and Functional Connectivity Reflects Available Cognitive Reserve in Multiple Sclerosis During Cognitive Rehabilitation (P1.1-025)
37. Serum neurofilament light chain levels and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study (S37.002)
38. Atrophied T2 lesion volume and cognitive outcomes in multiple sclerosis (P5.2-063)
39. Lower Total Cerebral Arterial Flow Contributes to Cognitive Performance in Multiple Sclerosis Patients (P5.2-037)
40. Functional Connectivity with the Default Mode Network Predicts Efficacy of Cognitive Rehabilitation in People with Multiple Sclerosis (P5.2-043)
41. Clinical and Conventional MRI Predictors of Cognitive Rehabilitation Efficacy in Multiple Sclerosis (P5.2-033)
42. The association between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis (P5.2-007)
43. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
44. Safety and Efficacy of Ocrelizumab in Multiple Sclerosis Patients with increased disability (P6.353)
45. Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease (P1.420)
46. Preservation of Functional Connectivity Moderates the Impact of White Matter Tract Disruption on Cognition in Multiple Sclerosis (S44.008)
47. Accelerated central atrophy in multiple sclerosis patients may be sex-specific (P3.357)
48. Accelerated subcortical atrophy following new lesion accrual in directly connected tracts is significant and appears limited to the first year (P3.350)
49. Subcortical gray matter atrophy is predicted by white matter lesions in directly connected tracts in multiple sclerosis (P4.364)
50. Maladaptive personality in multiple sclerosis and its relation to cognitive status (P4.342)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.